Medimmune
  • ABOUT MEDIMMUNE
    • Key Facts & Figures
    • Products
    • Facilities
    • At the Forefront
  • OUR CULTURE
    • History & Highlights
    • Visionaries at MedImmune
    • Executive Team
    • Corporate Responsibility
  • R & D
    • Pipeline
    • Drug Phase Chart
    • Biologics
    • Technologies & Approaches
    • Partnering
  • VENTURES
  • PRESS ROOM
  • CAREERS
  • CONTACT
  • Home >
    • News & Media

News and Media

For press releases:

2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Receive E-mail alerts

Subscribe to RSS feeds

December 17, 1999
MedImmune Announces Licensure of Manufacturing Facility
November 23, 1999
MedImmune Completes Acquisition of U.S. Bioscience
November 19, 1999
MedImmune to Exchange 0.15 Shares for Each U.S. Bioscience Share in Proposed Acquisition
November 4, 1999
Safety And Efficacy of Synagis® (Palivizumab) Reaffirmed After First Season’s Use; Medimmune Presents Data at Second World Congress of Pediatric Infectious Diseases
October 20, 1999
MedImmune Revenues Double in 1999 Third Quarter
September 22, 1999
MedImmune, Inc. to Acquire U.S. Bioscience, Inc.
September 15, 1999
MedImmune Licenses Catalytic Antibody to Treat Cocaine Overdose and AddictionMedImmune Licenses Catalytic Antibody to Treat Cocaine Overdose and Addiction
September 1, 1999
Abbott Announces Approval of Breakthrough Prevention
August 17, 1999
MedImmune Appoints Armando Anido, R.Ph. Senior Vice President of Sales and Marketing
July 21, 1999
Medimune Reports 1999 First Half Results
July 12, 1999
MedImmune and BioTransplant Announce Results of MEDI-507 Trial in Severe Steroid-Resistant Graft-Versus-Host Disease Patients
July 6, 1999
MedImmune and Pasteur Mérieux Connaught Report Presentation of New Data on Lyme Disease Vaccine Candidate at International Lyme Meeting
June 24, 1999
MedImmune Announces New Executive Appointments
May 21, 1999
European Committee for Proprietary Medicinal Products Adopts Positive Opinion on Synagis™ for Prevention of RSV
May 21, 1999
MedImmune to Redeem $60 Million of 7 Percent Convertible Subordinated Notes Due 2003
May 19, 1999
MedImmune and BioTransplant Announce Clinical at American Society of Transplantation Meeting
May 7, 1999
MedImmune Announces Presentation of Pharmacoeconomic Data for SynagisTM
April 21, 1999
MedImmune First Quarter Product Sales Nearly Triple
February 25, 1999
MedImmune and Ixsys Enter Four Product Antibody Alliance
January 27, 1999
MedImmune Reports Record Year
  • Terms and Conditions
  • |
  • Privacy Policy
  • |
  • Site Map
  • |
  • Contact Us
  • |
  • Glossary
Copyright © 2011 MedImmune, LLC. All rights reserved.